[8-K] ANAPTYSBIO, INC Reports Material Event

Rhea-AI Filing Summary

AnaptysBio's board has approved plans to explore separating its business into two independent, publicly traded companies. The company says the separation is expected to occur by the end of 2026. Management will host a conference call using a slide presentation to discuss the potential separation; the presentation is included as an exhibit. A press release describing the board action is also attached as an exhibit. The disclosure notes that the Item 7.01 information and the presentation are not deemed "filed" for Section 18 purposes.

Positive

• Board approval to explore separating the company into two independent, publicly traded entities
• Clear timeline communicated: separation is expected to occur by the end of 2026
• Transparent outreach via a conference call with a slide presentation filed as an exhibit
• Press release announcing the board action is attached as an exhibit

Negative

• None.

Insights

Corporate Governance Expert

TL;DR: Board approval to explore a corporate separation signals a strategic review with potential governance and stakeholder impacts.

The board's authorization to explore splitting the company into two publicly traded entities initiates a formal governance process that may involve creation of separate boards, reallocation of assets and personnel, and proxy or shareholder communications later in the process. Public disclosure of a conference call and slide presentation improves transparency at this stage. The company explicitly limited the legal status of the Item 7.01 materials, which is a common practice to manage liability while communicating strategic intent.

M&A / Corporate Transactions Specialist

TL;DR: Announcing exploration of a separation begins a potentially material structural change, but no transaction terms or impacts were disclosed.

The notice represents the start of a separation evaluation rather than a completed transaction. Key transaction details—structure, asset allocation, tax consideration, financing, or expected costs and benefits—are not provided. The guidance that the separation is expected by the end of 2026 gives a timeline for completion planning, but without metrics or milestones, investors cannot assess financial impact at this time.

0001370053false00013700532025-09-292025-09-29

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT PURSUANT TO

SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: September 29, 2025

(Date of earliest event reported)

ANAPTYSBIO, INC.

(Exact Name of Registrant as Specified in Charter)

Delaware			001-37985			20-3828755
(State or Other Jurisdiction of Incorporation)			(Commission File Number)			(IRS Employer Identification No.)

10770 Wateridge Circle, Suite 210,

San Diego, CA 92121

(Address of Principal Executive Offices, and Zip Code)

(858) 362-6295

(Registrant’s Telephone Number, Including Area Code)

Not Applicable

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			ANAB			The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01.    Regulation FD.

On September 29, 2025, AnaptysBio, Inc. (“AnaptysBio”) will host a conference call to discuss the potential separation of its business referred to and described under Item 8.01 below, and use a slide presentation in conjunction with the call. A copy of the presentation is filed herewith as Exhibit 99.1, and incorporated herein by reference.

The information in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

Item 8.01.    Other Events.

On September 29, 2025, AnaptysBio issued a press release (the “Press Release”) announcing that its Board of Directors approved plans to explore separating its business into two independent, publicly traded companies and that the separation is expected to occur by the end of 2026. A copy of the press release is attached as Exhibit 99.2 to this Current Report on Form 8-K.

Item 9.01.    Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number			Exhibit Title or Description
99.1			AnaptysBio, Inc. Investor Presentation, dated September 29, 2025.
99.2			Press release issued by AnaptysBio, Inc., dated September 29, 2025.
104			Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

						AnaptysBio, Inc.
Date: September 29, 2025						By:			/s/Dennis Mulroy
									Name: Dennis Mulroy
									Title: Chief Financial Officer

FAQ

What did AnaptysBio (ANAB) announce in this filing?

The company announced its Board approved plans to explore separating the business into two independent, publicly traded companies and disclosed related communications.

When does AnaptysBio expect the separation to occur?

The company stated the separation is expected to occur by the end of 2026.

Will AnaptysBio discuss the separation publicly?

Yes. Management will host a conference call and use a slide presentation; the presentation is filed as Exhibit 99.1.

Is there a press release about the board's decision?

Yes. A press release announcing the Board's approval to explore the separation is attached as Exhibit 99.2.

Are the Item 7.01 materials considered legally filed under Section 18?

No. The filing states the Item 7.01 information, including the presentation, is not deemed "filed" for purposes of Section 18 of the Exchange Act.